Latest period
$156M
YoY change
+31.2%
5Y CAGR
-0.7%
Peak year (FY2021)
$188M
Latest annual
$69.6M
Cash on Hand history chart for Ovid Therapeutics (OVID) from 2016 to 2025
Latest: $69.6M
Cash on Hand growth chart for Ovid Therapeutics (OVID) from 2016 to 2025
Latest: +31.2%
Cash on Hand history table for Ovid Therapeutics (OVID) from 2014 to 2025
| FY2025 | $69.6M | +31.2% | +$16.6M | ||
| FY2024 | $53.1M | -49.9% | -$52.8M | ||
| FY2023 | $106M | -18.0% | -$23.2M | ||
| FY2022 | $129M | -31.3% | -$58.8M | ||
| FY2021 | $188M | +160.7% | +$116M | ||
| FY2020 | $72M | -6.1% | -$4.71M | ||
| FY2019 | $76.7M | +84.9% | +$35.2M | ||
| FY2018 | $41.5M | -52.4% | -$45.6M | ||
| FY2017 | $87.1M | +67.7% | +$35.2M | ||
| FY2016 | $51.9M | -25.7% | -$18M | ||
| FY2015 | $69.9M | +1343.1% | +$65.1M | ||
| FY2014 | $4.85M | — | — |
- FY2025$69.6M+31.2%
- FY2024$53.1M-49.9%
- FY2023$106M-18.0%
- FY2022$129M-31.3%
- FY2021$188M+160.7%
- FY2020$72M-6.1%
- FY2019$76.7M+84.9%
- FY2018$41.5M-52.4%
- FY2017$87.1M+67.7%
- FY2016$51.9M-25.7%
- FY2015$69.9M+1343.1%
- FY2014$4.85M—
Cash on Hand values are taken from Ovid Therapeutics's reported balance sheets (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About Cash on Hand at Ovid Therapeutics (OVID)
According to Ovid Therapeutics's latest reported financial statements, the company's latest reported cash and short-term investments is $156M. Cash on hand here is cash, cash equivalents, and short-term investments reported at the end of each period — the most liquid assets on the balance sheet. Compare with total debt for net leverage and total assets for the share of assets held in cash.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
In 2025, Ovid Therapeutics (OVID) cash and short-term investments totalled $69.6M – surged 31.2% year-over-year.
Ovid Therapeutics cash and short-term investments has contracted on net over the period, with a -0.7% compound annual growth rate over 2020–2025 (5 years).
Ovid Therapeutics cash and short-term investments plunged from $188M in 2021 to $69.6M in 2025, a 62.9% drawdown.
The record annual cash and short-term investments stands at $188M, reached in 2021; the historical low of $4.85M was recorded in 2014.
Ovid Therapeutics Cash on Hand by Year
Ovid Therapeutics Cash on Hand 2025: $69.6M
2025's cash and short-term investments for Ovid Therapeutics came in at $69.6M, surged 31.2% from 2024.
Ovid Therapeutics Cash on Hand 2024: $53.1M
Ovid Therapeutics posted cash and short-term investments of $53.1M in 2024, plunged 49.9% below 2023.
Ovid Therapeutics Cash on Hand 2023: $106M
In 2023, Ovid Therapeutics reported cash and short-term investments of $106M, declined 18.0% below 2022.
Ovid Therapeutics Cash on Hand 2022: $129M
Ovid Therapeutics cash and short-term investments in 2022 was $129M, plunged 31.3% below 2021.
Ovid Therapeutics Cash on Hand 2021: $188M
Ovid Therapeutics cash and short-term investments in 2021 was $188M.
See more financial history for Ovid Therapeutics (OVID).
Sector peers by Cash on Hand
Healthcare peers of Ovid Therapeutics (OVID), ranked by their latest cash and short-term investments
| $28.1B | |
| $20.1B | |
| $14.6B | |
| $10.1B | |
| $9.13B | |
| $7.27B | |
| $5.26B | |
| $4.24B |
- $28.1B
- $20.1B
- $14.6B
- $9.13B
- $7.27B
- $5.26B
- $4.24B
Frequently asked questions
Ovid Therapeutics (OVID) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation
How this company returns cash to shareholders — buybacks, dividends, and stock splits.